MAROKO133 Breaking ai: 10,200-ton nuclear submarine for US Navy: Korean firm proposes to b

📌 MAROKO133 Update ai: 10,200-ton nuclear submarine for US Navy: Korean firm propo

A Seoul-based company has expressed its intention to build nuclear-powered submarines for the U.S. Navy. Hanwha Group claims that its Philadelphia plant could support construction of advanced submarines, such as the Virginia-class, if the U.S. government approves and formalizes the plan.

The announcement from the South Korean defense giant came at a time when the U.S. Navy faces growing pressure to expand its submarine fleet and overcome long-standing production delays at existing shipyards.

Ready to fulfil the ability to build nuclear submarines

Hanwha acquired the Philadelphia shipyard roughly a year ago and has since been investing in modernizing its facilities, improving efficiency, and strengthening its workforce. The company is presenting the yard as part of the solution to the U.S. Navy’s submarine production bottleneck, arguing that additional shipbuilding capacity is essential as demand continues to exceed what current U.S. yards can deliver on schedule.

“The U.S. government’s commitment to nuclear-powered submarine capability, its own, and of the allies is very strong,” said Alex Wong, global chief strategy officer at Hanwha Group during the Hanwha’s media day at the shipyard in Philadelphia on Monday. “We stand ready to fulfil the ability to build those submarines here in Philly when the governments are ready.”

Nuclear-powered submarines are among the most complex military platforms

The proposal is significant because nuclear-powered submarines are among the most complex military platforms to build. Constructing them requires strict safety, security, and regulatory approvals, along with highly specialized infrastructure and skilled labor. Historically, only a small number of U.S. shipyards have been certified to perform this work, meaning Hanwha’s plan would represent an expansion of the U.S. naval industrial base rather than a replacement of existing builders.

The Virginia class has several innovations that significantly enhance its warfighting capabilities, including in littoral — or coastal — operations. The class has special features to support SOF, including a reconfigurable torpedo room which can accommodate a large number of SOF personnel and all their equipment for prolonged deployments, as well as future off-board payloads. Its submerged displacement is around 10,200 tons.

More broadly, the move reflects deepening defense-industrial cooperation between the United States and South Korea. It aligns with U.S. efforts to strengthen shipbuilding capacity through allied investment while also offering potential economic benefits for Philadelphia. Although major hurdles remain before any nuclear submarine construction could begin, Hanwha’s proposal highlights how international partnerships may play a growing role in supporting U.S. naval readiness in the years ahead.

The announcement from Wong came as recently President Donald Trump told a press conference that Hanwha would participate in building frigates for the US Navy. He called Hanwha “a good company”, referring to its planned US$5 billion expansion in the Philly Shipyard, which it bought in 2024 for US$100 million.

With only 24 Virginia-class submarines commissioned to date, the United States needs to build at least two nuclear-powered submarines every year to reach the goal. However, the nation has produced an average of just 1.2 annually.

🔗 Sumber: interestingengineering.com

📌 MAROKO133 Update ai: Scientists Identify Possible Game Changing Treatment for Al

Scientists at Northwestern University used a novel compound to arrest early stages of Alzheimer’s disease in mice — setting the stage, if all goes well, for a groundbreaking treatment in which the debilitating condition can be controlled like high cholesterol.

The researchers discovered an unknown subtype of a protein in the brain which can lead to Alzheimer’s disease, according to a new paper the team published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, and they demonstrated that their new novel compound, dubbed NU-9, can attack this brain protein and stop the disease from taking hold — in mice, at least.

“Most people are used to monitoring their cholesterol levels,” said Richard Silverman, a chemistry professor at Northwestern who coauthored the paper and invented NU-9, in a university statement. “If you have high cholesterol, it doesn’t mean that you will have a heart attack soon. But it’s time to take drugs to lower your cholesterol levels to prevent that heart attack from happening down the road. NU-9 could play a similar role. If someone has a biomarker signaling Alzheimer’s disease, then they could start taking NU-9 before symptoms appear.”

For this particular experiment, the team took lab mice that were predisposed to develop Alzheimer’s disease but hadn’t developed the condition yet, and started giving them an oral dose of NU-9 for 60 days. They were especially curious about how NU-9 would impact the protein amyloid beta oligomers, which accumulate in the brain hand in hand with signs of Alzheimer’s.

After closely examining the mice brains, scientists observed that NU-9 essentially decreased the presence of a previously unknown subtype of amyloid beta oligomers that they dubbed ACU193+ AβOs. This specific type of protein was associated with brain inflammation that shows up before people are diagnosed with Alzheimer’s. When the team introduced NU-9 into these mice brains, they found that NU-9 tamped down the presence of this toxic protein and hence decreased inflammation.

“These results are stunning,” William Klein, a Northwestern neuroscience professor and the paper’s principal investigator, summed up in the university statement.

“There are a couple early diagnostic blood tests for Alzheimer’s disease in development,” he said. “The promise of better early diagnostics — combined with a drug that could stop the disease in its tracks — is the goal.”

The next step now is to experiment and analyze the effectiveness of NU-9 in the later stages of Alzheimer’s disease, according to the scientists.

Silverman originally invented NU-9, a synthetic compound with the technical name of cyclohexane-1,3-dione, in an effort to identify chemicals that can tackle neurological diseases. Besides Alzheimer’s disease, the NU-9 has proved effective against Amyotrophic lateral sclerosis (ALS) and possibly frontotemporal degeneration, all three of which involve the appearance of toxic protein in brains.

More on Alzheimer’s disease: Scientists Intrigued by Old Drug That Reverses Signs of Alzheimer’s in Mice

The post Scientists Identify Possible Game Changing Treatment for Alzheimer’s Disease That Could Control It Like High Cholesterol appeared first on Futurism.

🔗 Sumber: futurism.com